As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

RAS Screens and Assays at FNLCR

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

A primary goal of the RAS Initiative at the Frederick National Laboratory for Cancer Research (FNLCR) is to develop assays for RAS activity, localization, and signaling and adapt those assays so they can be used for finding new drug candidates. The assays are of two broad types: in vitro assays that use purified proteins and in vivo assays that use live cells. Adapting assays for use in screening campaigns requires that all aspects of each assay be thoroughly understood and controlled, so that tens or hundreds of thousands of data points can be confidently assessed. The end products are highly validated screening protocols that can be applied by partner organizations to their own libraries of small molecules or natural products.

  • RAS Models Development

    The cell lines engineered and characterized by this group are essential components of the RAS Initiative screening efforts

  • RAS Image-Based Screens

    This laboratory develops screens based on live cell imaging of labeled RAS molecules.

  • RAS Drug Discovery

    This group has developed and validated in vitro and in vivo assays suitable for screening large libraries of candidate drug compounds.